A Coordination Card of Care Relative to the Medicinal Treatments Got Out of it From Hospitalization

NCT03293966 | Completed

• 1 other identifier: PRIMACIE
• Study Type: observational
• Target: 47
• Locations: 1 country
• Sites: 1

Brief Summary

The continuity of the medicinal care between the city and the hospital stays a major organizational stake and of safety of patients' therapeutic care.This takeover is more complex when it concerns pathology needed lots of hospitalization and included the intervention of multiple healthcare practionners. This is clearly the case of cancer coverage. The optimization of the therapeutic suppor in town is based on pharmaceutical advice strengthening but also on the pharmaceutical analysis to check the entire treatments' prescription and eventual medicinal interactions which ensue from it.That's why it's important to have a medicinal conciliation that takes into account all the medecine taken or have to be taken by the patient. A specific support was developped by nurses , doctors and pharmacist ; it's a care coordination card that can be put easely in a pocket by the patient. The aim of the study is that this card can be also used as a communication tools by sharing the prescription done at the release of hospital by using an IT link (flea datamatrix) for the patients Via the use of an IT link (flea datamatrix) for the patients whose pathology is complex in term of extra hospital coverage.

Conditions

Treatment Related Cancer

Outcome Measures

Primary Outcomes (1)

• Composite criteria including all the dysfunctions noticed at the release of the hospital prescription intended to be dispensed in town.

  7days+/- 2 days

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients admitted to thoracic pneumology and oncology treated with anticancer drugs will receive a medication conciliation. Patients integrating the study will be patients who have benefited from the entire process of medication conciliation (entry and exit) and returning home. The included patients must have attended the same pharmacy for at least 3 months (according to the patient declaration).

You may qualify if:

• all patient admitted in onco-thoracic service
• Handled by an anticancer agent
• Having frequented the same city pharmacy for at least 3 months

You may not qualify if:

• hospitalization above 21 days
• refusing participation
• palliative care
• misunderstanding of french language
• frequenting several pharmacy

Sponsors & Collaborators

• Fondation Hôpital Saint-Joseph: lead

Study Sites (1)

Groupe Hospitalier Paris Saint Joseph

Paris, Île-de-France Region, 75014, France

Location

MeSH Terms

Conditions

Neoplasms, Second Primary

Condition Hierarchy (Ancestors)

Neoplasms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2017
• First Posted: September 26, 2017
• Study Start: June 1, 2016
• Primary Completion: February 28, 2017
• Study Completion: December 31, 2017
• Last Updated: June 1, 2018

Record last verified: 2018-05

Locations

FR (1)